Caixia Tian1,2, Lian Li2, Tanxin Liu3, Xin Qu2, Yurong Qiu4. 1. Laboratory Medicine Centre, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China. 2. Department of Clinical Laboratory Science, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, People's Republic of China. 3. Division of Nephrology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, People's Republic of China. 4. Laboratory Medicine Centre, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China. qiuyuronggz@126.com.
Abstract
BACKGROUND: M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) have recently been identified as target antigens for patients with idiopathic membranous nephropathy (IMN). The prevalence of PLA2R and THSD7A in the serum of MN patients deserves further investigation. METHODS: Here, we studied the presence of anti-PLA2R and anti-THSD7A antibodies in patients with biopsy-proven IMN (n = 212), secondary membranous nephropathy (SMN, n = 118), and other kidney diseases (n = 84). The progress of 49 IMN patients [anti-PLA2R(+), n = 27; anti-THSD7A(+), n = 6; anti-PLA2R(-) and anti-THSD7A(-) dual negative, n = 16] who received immunosuppressive therapy was observed for 12 months. Serum concentrations of antibodies against PLA2R and THSD7A were detected using an indirect immunofluorescent assay. RESULTS: One hundred fifty-two (71.7%) IMN patients and 11 (9.3%) SMN patients were identified as anti-PLA2R(+) anti-THSD7A(-). Five (2.4%) IMN patients and two (1.7%) SMN patients were identified as anti-THSD7A(+) anti-PLA2R(-). One of the IMN patients was identified as anti-PLA2R(+) and anti-THSD7A(+). The rate of partial remission was lower in anti-PLA2R(+) patients than in anti-PLA2R(-) patients 3 months (P = 0.045) and 6 months (P = 0.006) after immunosuppressive therapy. The rate of complete remission was lower in anti-PLA2R(+) patients than in anti-PLA2R(-) patients 12 months (P = 0.037) after immunosuppressive therapy. CONCLUSIONS: The serum concentration of anti-PLA2R antibodies may be used as a sensitive and specific marker for diagnosing IMN. Immunosuppressive therapy is more effective for IMN patients who are anti-PLA2R(-) than for those who are anti-PLA2R(+).
BACKGROUND: M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) have recently been identified as target antigens for patients with idiopathic membranous nephropathy (IMN). The prevalence of PLA2R and THSD7A in the serum of MN patients deserves further investigation. METHODS: Here, we studied the presence of anti-PLA2R and anti-THSD7A antibodies in patients with biopsy-proven IMN (n = 212), secondary membranous nephropathy (SMN, n = 118), and other kidney diseases (n = 84). The progress of 49 IMN patients [anti-PLA2R(+), n = 27; anti-THSD7A(+), n = 6; anti-PLA2R(-) and anti-THSD7A(-) dual negative, n = 16] who received immunosuppressive therapy was observed for 12 months. Serum concentrations of antibodies against PLA2R and THSD7A were detected using an indirect immunofluorescent assay. RESULTS: One hundred fifty-two (71.7%) IMN patients and 11 (9.3%) SMNpatients were identified as anti-PLA2R(+) anti-THSD7A(-). Five (2.4%) IMN patients and two (1.7%) SMNpatients were identified as anti-THSD7A(+) anti-PLA2R(-). One of the IMN patients was identified as anti-PLA2R(+) and anti-THSD7A(+). The rate of partial remission was lower in anti-PLA2R(+) patients than in anti-PLA2R(-) patients 3 months (P = 0.045) and 6 months (P = 0.006) after immunosuppressive therapy. The rate of complete remission was lower in anti-PLA2R(+) patients than in anti-PLA2R(-) patients 12 months (P = 0.037) after immunosuppressive therapy. CONCLUSIONS: The serum concentration of anti-PLA2R antibodies may be used as a sensitive and specific marker for diagnosing IMN. Immunosuppressive therapy is more effective for IMN patients who are anti-PLA2R(-) than for those who are anti-PLA2R(+).
Authors: Masa Knehtl; Hanna Debiec; Prochore Kamgang; Patrice Callard; Jacques Cadranel; Pierre Ronco; Jean-Jacques Boffa Journal: Am J Kidney Dis Date: 2010-11-17 Impact factor: 8.860
Authors: Barbora Svobodova; Eva Honsova; Pierre Ronco; Vladimir Tesar; Hanna Debiec Journal: Nephrol Dial Transplant Date: 2012-12-06 Impact factor: 5.992
Authors: Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant Journal: N Engl J Med Date: 2009-07-02 Impact factor: 91.245
Authors: Julia M Hofstra; Hanna Debiec; Colin D Short; Timotheé Pellé; Robert Kleta; Peter W Mathieson; Pierre Ronco; Paul E Brenchley; Jack F Wetzels Journal: J Am Soc Nephrol Date: 2012-09-06 Impact factor: 10.121
Authors: Christopher P Larsen; Nidia C Messias; Fred G Silva; Erick Messias; Patrick D Walker Journal: Mod Pathol Date: 2012-11-30 Impact factor: 7.842
Authors: Maryline Fresquet; Thomas A Jowitt; Jennet Gummadova; Richard Collins; Ronan O'Cualain; Edward A McKenzie; Rachel Lennon; Paul E Brenchley Journal: J Am Soc Nephrol Date: 2014-10-06 Impact factor: 10.121
Authors: Aikaterini Nikolopoulou; Catarina Teixeira; H Terry Cook; Candice Roufosse; Thomas H D Cairns; Jeremy B Levy; Charles D Pusey; Megan E Griffith Journal: Clin Kidney J Date: 2020-04-15